Master jet base

Introducing iKO Media Group's Revolutionary Video Network Monitoring Tool: iKOVIEW

Retrieved on: 
Wednesday, May 17, 2023

PFAFFIKON, Switzerland, and TEL-AVIV, Israel, May 17, 2023 /PRNewswire/ -- iKO Media Group is proud to announce the launch of iKOVIEW, a cutting-edge video network monitoring product developed in collaboration with Alvalinks. Setting new industry standards, iKOVIEW is the most advanced SRT monitoring tool available in the market today, delivering unparalleled capabilities for monitoring and ensuring the quality of video links.

Key Points: 
  • PFAFFIKON, Switzerland, and TEL-AVIV, Israel, May 17, 2023 /PRNewswire/ -- iKO Media Group is proud to announce the launch of iKOVIEW, a cutting-edge video network monitoring product developed in collaboration with Alvalinks.
  • Setting new industry standards, iKOVIEW is the most advanced SRT monitoring tool available in the market today, delivering unparalleled capabilities for monitoring and ensuring the quality of video links.
  • Alvalinks empowers iKO to monitor next-generation services, provide superior quality of service, and ensure real-time monitoring of all SRT video transmission feeds.
  • Alvalinks' Cloudrider is the sole video-oriented network monitoring mechanism capable of deep-diving into network inconsistencies and effectively supporting video organizations in their pursuit of perfection.

At Week 104, 75% of Patients with Ulcerative Colitis Taking Mirikizumab Maintained Symptomatic Remission in Phase 2 Study

Retrieved on: 
Friday, October 1, 2021

Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.

Key Points: 
  • Both analyses will be presented virtually at United European Gastroenterology Week (UEG Week), taking place October 3-5, 2021.
  • Among patients treated with mirikizumab, results in symptomatic remission, rectal bleeding remission and stool frequency remission were comparable between biologic-nave patients and those who had prior experience with biologics.
  • Efficacy and Safety of Mirikizumab in Patients with Ulcerative Colitis: 104-Week Results from a Phase 2 Randomized Controlled Trial
    186 patients with moderately to severely active UC received treatment with mirikizumab.
  • At two years, 85.9% (67/78) of patients achieved rectal bleeding remission and 84.6% (66/78) of patients achieved stool frequency remission.